Creating the Mutational Profile of Myeloid Tumors With CENTOGENE's Myeloid Tumor Panel

Myeloid malignancies are clonal diseases of hematopoietic progenitor cells. They result from genetic and epigenetic alterations that disrupt processes such as proliferation, differentiation and self-renewal of hematopoietic cells. Myeloid tumors represent the fourth most frequently diagnosed cancer in economically developed countries.

The majority of myeloid tumors contain high numbers of somatic mutations, which are genetic changes that are not inherited but rather created within the tumor itself. Unlike inherited “germline” mutations these
somatic mutations can occur in any of the cells of the body and are not transmitted to offsprings.

Genetic testing of myeloid tumor at CENTOGENE can provide you with the mutational profile of the myeloid tumor and with valuable information for diagnostic decisions, prognosis, therapeutic approaches and patient counseling.

The goals of genetic testing for myeloid tumor are to identify:

  • Myeloid tumors that may respond to targeted therapies by assessing multiple gene targets
  • Specific mutations within genes known to be associated with response or resistance to specific cancer therapies
  • Mutations that may help determine prognosis for patients with myeloid tumors
  • The best therapeutic strategy for each patient
  • The diagnosis that will reassure both patient and physician about the relevant health problem and all the possible solutions to improve it

When to suggest the myeloid tumor panel:

The myeloid tumor panel can be recommended for the following patients:

  • Individuals with myeloid tumor: acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). The results of this genetic test can be useful for assessing the prognosis and guiding the treatment of individuals with myeloid
  • Patients without clinical diagnosis but with classical clinical symptoms and possible changes in the blood cells morphology and counts.
  • Individuals with early stage disease where a mutational profile from multiple genes informs diagnosis or disease stratification, prognosis, and treatment options.
  • For late stage cancers, the test is designed to evaluate options for alternative treatments, including
    targeted therapies.

Benefits of myeloid tumor panel genetic testing:

  • Covers important regions within 53 genes and more than 1,000 mutations associated with myeloid
  • Enables rapid eligibility identification and patient stratification for clinical trials
  • Allows longitudinal and serial molecular monitoring throughout the clinical trial process
  • Can be conducted with fresh or frozen/archived blood and bone marrow samples
  • Does not require special shipping or storage provisions
  • Employs expert analysis from a CLIA-certified lab
  • Identifies patients at high risk who are less likely to respond well to treatment
  • Helps determining the intensity of treatment each patient should receive.

CENTOGENE´s myeloid tumor panel offer:

Myeloid tumor panel targets important regions within 53 genes that are frequently mutated in myeloid

  • CENTOGENE is offering comprehensive myeloid tumor panel which includes library preparation,
    sequencing, and data analysis and reporting in a cost-effective way and with a turnaround time of only 10 days.
  • Myeloid tumor panel collectively assesses important regions within 53 genes with high-accuracy, high-sensitivity and at a mean coverage depth of 5,000x.
  • Myeloid tumor panel enables clinical researchers and physicians to access expert-defined content to investigate genomic features associated with hematological malignancies.
  • Myeloid tumor panel includes the following genes (the numbers in brackets indicate the covered exons from the gene): ABL1 (Ex4-Ex6), ASXL1 (Ex12), ATRX (Ex08-10, Ex17-31), BCOR (full gene), BCORL1 (full gene), BRAF (Ex15), CALR (Ex09), CBL (Ex08-E09), CBLB (Ex09, Ex10), CBLC (Ex09, Ex10), CDKN2A (full gene), CEBPA (full gene), CSF3R (Ex14-Ex17), CUX1 (full gene), DNMT3A (full gene), ETV6/TEL (full gene), EZH2 (full gene), FBXW7 (Ex09-Ex11), GATA1 (Ex02), GATA2 (Ex02-Ex06), GNAS (Ex08-Ex09), HRAS (Ex02-Ex03), IDH1 (Ex04), IDH2 (Ex04), IKZF1 (full gene), JAK2 (Ex12, Ex14), JAK3 (Ex13), KDM6A (full gene), KIT (Ex2,Ex08-Ex11, Ex13, Ex17), KRAS (E02-E03), MLL (Ex05-Ex08), MPL (Ex10), MYD88 (Ex03, Ex04, Ex05), NOTCH1 (Ex26-Ex27, Ex34), NPM1 (Ex12), NRAS (Ex02-Ex03), PDGFRA (Ex12, Ex14, Ex18), PHF6 (full gene), PTEN (Ex05, Ex07), PTPN11 (Ex3, Ex13), RAD21 (full gene), RUNX1 (full gene), SETBP1 (Ex04 (partial)), SF3B1 (Ex13-Ex16), SMC1A (Ex2, Ex11, Ex16, Ex17), SMC3 (Ex10, Ex13, Ex19, Ex23, Ex25, Ex28), SRSF2 (Ex01), STAG2 (full gene), TET2 (Ex3-Ex11), TP53 (Ex2-Ex11), U2AF1 (Ex02, Ex06), WT1 (Ex07, Ex09), ZRSR2 (full gene)).

-    Myeloid tumor panel utilizes NGS sequencing and Illumina Platform

Sample Requirements

-    1-3 ml of bone marrow aspirate or 1µg of DNA from bone marrow or blood or 1ml of EDTA blood

Why to choose CENTOGENE´s myeloid tumor panel:

  1. We offer a short turnaround time to the best price.
  2. We combine medical and technical expertise.
  3. Our reports deliver the results in an easy and understandable way, and if needed, recommendations for additional testing are included.

For more information please download our information sheets:

Got Some Feedback?